ArticleClinical and translational radiation oncology2026
Feasibility of omitting regional nodal irradiation in cT1-2N1 breast cancer with ypN1 disease after neoadjuvant chemotherapy (KROG 21-06).
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the effect of regional nodal irradiation (RNI) in breast cancer patients with 1-3 residual nodal metastases (ypN1) after neoadjuvant chemotherapy (NAC). Methods: We retrospectively reviewed the medical records of breast cancer patients with clinical T1-2N1 disease who received NAC followed by surgery and postoperative radiotherapy between 2005 and 2017. Patients with 1-3 pathologically positive lymph nodes (ypN1) after axillary dissection were included. Univariate and multivariate analyses were performed to identify the prognostic factors for locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS). Results: The median follow-up duration was 88.9 months (range, 5.0-200.1). A total of 245 patients were included and RNI was administered in 84.5% (n = 207). Lymphatic invasion and extranodal extension were more frequent in patients who received RNI compared with those who did not ( Conclusion: RNI was not associated with additional survival benefit in cT1-2N1 breast cancer patients with ypN1 disease after NAC. These findings warrant further validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.